Teresi ME - Search Results

1

Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis.

Ahrens RC, Standaert TA, Launspach J, Han SH, Teresi ME, Aitken ML, Kelley TJ, Hilliard KA, Milgram LJ, Konstan MW, Weatherly MR, McCarty NA. Ahrens RC, et al. Among authors: teresi me. Pediatr Pulmonol. 2002 Feb;33(2):142-50. doi: 10.1002/ppul.10043. Pediatr Pulmonol. 2002. PMID: 11802252

2

A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis.

McCarty NA, Standaert TA, Teresi M, Tuthill C, Launspach J, Kelley TJ, Milgram LJ, Hilliard KA, Regelmann WE, Weatherly MR, Aitken ML, Konstan MW, Ahrens RC. McCarty NA, et al. Pediatr Pulmonol. 2002 Feb;33(2):90-8. doi: 10.1002/ppul.10041. Pediatr Pulmonol. 2002. PMID: 11802244 Clinical Trial.

3

Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.

Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators. Mayer-Hamblett N, et al. Pediatr Pulmonol. 2013 Oct;48(10):943-53. doi: 10.1002/ppul.22693. Epub 2013 Jul 2. Pediatr Pulmonol. 2013. PMID: 23818295 Free PMC article. Clinical Trial.

4

Asthma stability after oral prednisone: a clinical model for comparing inhaled steroid potency.

Ahrens RC, Teresi ME, Han SH, Donnell D, Vanden Burgt JA, Lux CR. Ahrens RC, et al. Among authors: teresi me. Am J Respir Crit Care Med. 2001 Oct 1;164(7):1138-45. doi: 10.1164/ajrccm.164.7.2008112. Am J Respir Crit Care Med. 2001. PMID: 11673199 Clinical Trial.

5

Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW; EPIC Investigators. Mayer-Hamblett N, et al. Pediatr Pulmonol. 2012 Feb;47(2):125-34. doi: 10.1002/ppul.21525. Epub 2011 Aug 9. Pediatr Pulmonol. 2012. PMID: 21830317 Free PMC article. Clinical Trial.

6

Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.

Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group. Cogen J, et al. Pediatr Pulmonol. 2015 Aug;50(8):763-70. doi: 10.1002/ppul.23217. Epub 2015 Jun 9. Pediatr Pulmonol. 2015. PMID: 26061914 Free PMC article.

7

Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.

Rowe SM, Liu B, Hill A, Hathorne H, Cohen M, Beamer JR, Accurso FJ, Dong Q, Ordoñez CL, Stone AJ, Olson ER, Clancy JP; VX06-770-101 Study Group. Rowe SM, et al. PLoS One. 2013 Jul 26;8(7):e66955. doi: 10.1371/journal.pone.0066955. Print 2013. PLoS One. 2013. PMID: 23922647 Free PMC article. Clinical Trial.

8

Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis.

Singh S, Hornick D, Fedler J, Launspach JL, Teresi ME, Santacroce TR, Cavanaugh JE, Horan R, Nelson G, Starner TD, Zabner J, Durairaj L. Singh S, et al. Among authors: teresi me. J Cyst Fibros. 2020 Jan;19(1):108-113. doi: 10.1016/j.jcf.2019.06.016. Epub 2019 Jul 18. J Cyst Fibros. 2020. PMID: 31327670 Free PMC article. Clinical Trial.

9

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group. Ramsey BW, et al. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185. N Engl J Med. 2011. PMID: 22047557 Free PMC article. Clinical Trial.

10

Tobramycin as a pharmacologic tracer to compare airway deposition from nebulizers.

Asmus MJ, Stewart BA, Milavetz G, Teresi ME, Han SH, Wang D, Ahrens RC. Asmus MJ, et al. Among authors: teresi me. Pharmacotherapy. 2002 May;22(5):557-63. doi: 10.1592/phco.22.8.557.33202. Pharmacotherapy. 2002. PMID: 12013353

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters